Following up tumor-specific regulatory T cells in cancer patients

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Zitvogel, Laurence ^a,b,c,d   Tanchot, Corinne ^e   Granier, Clemence ^f   Tartour, Eric ^e,f  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CIC BT507   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cancer vaccine; Immunomonitoring; Immunosuppression; Regulatory T cell; Tumor antigen

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; GLYCOPROTEIN GP 100; INTERLEUKIN 10; MACROPHAGE DERIVED CHEMOKINE; NY ESO 1 ANTIGEN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

ANTIGEN SPECIFICITY; ANTIGENIC VARIATION; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CELL FUNCTION; CELL SUBPOPULATION; CYTOKINE PRODUCTION; DENDRITIC CELL; FOLLOW UP; GENE AMPLIFICATION; HUMAN; INTRACELLULAR SPACE; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886944764     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25444     Document Type: Article

References (15)

1. Schmidt H, Ge Y, Hartmann F, Conrad H, Klug F, Nittel S, et al. HLA Class II tetramers reveal tissuespecific regulatory T cells that suppress T-cell responses in breast carcinoma patients. OncoImmunology 2013; In press; http://dx.doi.org/10.4161/onci.24962
2. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19:217-23; PMID:17306521; http://dx.doi.org/10.1016/j.coi.2007.02.004
3. Tanchot C, Terme M, Pere H, Tran T, Benhamouda N, Strioga M, et al. Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance. Cancer Microenviron 2012; PMID:23104434; http://dx.doi.org/10.1007/ s12307-012-0122-y
4. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007 104:12087-92; PMID:17615234; http://dx.doi. org/10.1073/pnas.0704672104
5. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202:919-29; PMID:16186184; http://dx.doi.org/10.1084/jem.20050463
6. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73:539-49; PMID:23108136; http://dx.doi. org/10.1158/0008-5472.CAN-12-2325
7. Ménétrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res 2009; 69:7895-8; PMID:19808962; http://dx.doi. org/10.1158/0008-5472.CAN-09-1642
8. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853-62; PMID:21908423; http:// dx.doi.org/10.1182/blood-2011-01-329656
9. Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology 2012; 1:642-8; PMID:22934256; http://dx.doi.org/10.4161/onci.20298
10. Sainz-Perez A, Lim A, Lemercier B, Leclerc C. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 2012; 72:3557-69; PMID:22573714; http://dx.doi.org/10.1158/0008-5472.CAN-12-0277
11. Mandapathil M, Szczepanski M, Harasymczuk M, Ren J, Cheng D, Jackson EK, et al. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 2012; 1:659-69; PMID:22934258; http://dx.doi.org/10.4161/onci.20387
12. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 2012; 1:326-33; PMID:22737608; http://dx.doi.org/10.4161/onci.18852
13. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21; PMID:19809157
14. Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 2009; 69:8085-93; PMID:19808957; http://dx.doi.org/10.1158/0008- 5472.CAN-09-2226
15. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; PMID:22842478; http://dx.doi. org/10.1038/nm.2883